Form 4: ICU Medical CEO Vivek Jain Executes Option and Sells Shares Under 10b5-1 Plan

ICU Medical's Chairman and CEO, Vivek Jain, exercised stock options and sold shares of common stock on November 1, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On November 1, 2024, Vivek Jain, Chairman and CEO of ICU Medical Inc., exercised non-qualified stock options to acquire 12,000 shares of common stock at a price of $88.76 per share.
• Simultaneously, Jain sold a total of 11,990 shares of ICU Medical common stock in multiple transactions at weighted average prices ranging from $170.7504 to $173.597.
• These transactions were executed under a pre-existing Rule 10b5-1 trading plan adopted on March 15, 2024.
• Following these transactions, Jain directly owns 104,593 shares of ICU Medical common stock and indirectly owns 88,698 shares through a trust.
• He also holds 13,373 derivative securities (non-qualified stock options).

Sentiment

Score: 6

Explanation: Neutral sentiment as the transactions are part of a pre-planned trading strategy. The CEO exercising options and selling shares is a common occurrence.

Positives

• The transactions were executed under a pre-arranged 10b5-1 trading plan, which is generally viewed as a transparent and compliant way for insiders to manage their stock holdings.

Risks

• While the sales are under a 10b5-1 plan, large sales by a CEO could be perceived negatively by some investors.

Industry Context

Insider transactions are common, and the use of 10b5-1 plans is a standard practice to avoid accusations of trading on non-public information. The market will likely assess the transactions in light of ICU Medical's overall performance and outlook.

Comparison to Industry Standards

• It's common for executives at publicly traded companies like ICU Medical to have stock option grants as part of their compensation packages.
• The use of 10b5-1 trading plans is a widespread practice among corporate insiders to manage their stock sales in compliance with SEC regulations, similar to practices at companies like Medtronic or Boston Scientific.
• The reported weighted average sale prices are within a typical range for market transactions of this nature.

Stakeholder Impact

• The transactions could have a minor impact on shareholders depending on how the market interprets the CEO's stock sales.

Key Dates